263 results about "Insulin sensitivity" patented technology

The invention relates to an integrated management system for diabetic patients, which comprises the following steps of: constructing a high-dimensional metabolic data model, performing multi-modal fusion on genome information, metabolome data and life behavior data, and mining a potential mode of metabolic characteristics of the patients; carrying out patient typing by utilizing a clustering algorithm comprising a self-organizing mapping network, and identifying different metabolism types comprising an insulin resistance type and an insulin secretion insufficiency type; developing a hierarchical management strategy based on a typing result, wherein the hierarchical management strategy comprises diet, exercise and medicine intervention schemes for different types; collecting dynamic quantitative indexes of the metabolic load, and integrating the blood glucose fluctuation amplitude, insulin sensitivity and daily nutrition intake of the patient; constructing a metabolic load prediction model, and combining a time sequence deep learning algorithm with real-time data, including blood glucose, diet and exercise, of a patient to measure a future metabolic load; and establishing a causal relationship model between patient behaviors and metabolic reactions, and analyzing an interaction mode of diet, exercise and metabolic loads by adopting a causal inference technology.

The invention discloses a personalized medical health service recommendation system based on big data analysis, and belongs to the technical field of medical health services. The synchronization module is used for generating a standardized data stream according to dynamic blood glucose monitoring data and an original heart rate variability signal; the analysis module is used for generating a diet time sequence data stream according to the intake event timestamp; the blood glucose feature extraction module is used for extracting data from the standardized data stream; the insulin sensitivity analysis module is used for generating an insulin sensitivity factor matrix; the nutrition analysis module is used for generating a carbohydrate equivalent time distribution vector and a dietary fiber intake intensity value; the feature fusion module is used for generating a fusion feature vector according to the blood glucose drift trend coefficient, the insulin sensitive factor matrix and the carbohydrate equivalent time distribution vector; the risk assessment module is used for generating a hypoglycemia risk probability value according to the fusion feature vector; and the recommendation generation module is used for generating a personalized service recommendation set according to the hypoglycemia risk probability value.

The invention relates to application of mouse combined lactobacillus. According to the application disclosed by the invention, the lactobacillus murins DSM 28683 can be applied to the preparation of a product for treating type 2 diabetes mellitus or a product for reducing body fat. A T2D mouse is subjected to intragastric administration by using the Ligilbacillus murins DSM 28683, and it is found that the Ligilbacillus murins DSM 28683 can significantly improve metabolism of the T2D mouse, effectively improve insulin sensitivity of the T2D mouse, reduce body weight and improve fatty liver, and has a good application prospect in treatment of type 2 diabetes mellitus.

The invention relates to an application of an Sdccag3 gene in preparation of a weight-reducing medicine for regulating glucose and lipid metabolism. The Sdccag3 gene is used as an action target to be applied to preparation or screening of the weight-reducing medicine for regulating glucose and lipid metabolism, and the nucleotide sequence of the Sdccag3 gene is as shown in SEQ ID No. 1. According to the application disclosed by the invention, the specific overexpressed Sdccag3 in adipose tissues in a mouse body can obviously inhibit the increase of the blood fat level, and the overexpressed Sdccag3 can also obviously improve the poor glucose tolerance, improve the insulin sensitivity, reduce the levels of serum triglyceride, cholesterol and low-density lipoprotein cholesterol of an obese mouse, improve the poor glucose tolerance and improve the insulin sensitivity. The insulin sensitivity is improved, obesity-related glycolipid metabolism is effectively regulated and controlled, the effect of reducing blood lipid and blood sugar is achieved, and the compound can be used for preparing weight-losing drugs for reducing blood lipid and blood sugar.

A wearable drug delivery device, techniques, and computer-readable media that provide an application that implements a diabetes treatment plan for a user are described. The drug delivery device may include a controller operable to direct operation of the wearable drug delivery device. The controller may provide a selectable activity mode of operation for the user. Operation of the drug delivery device in the activity mode of operation may reduce a likelihood of hypoglycemia during times of increased insulin sensitivity for the user and may reduce a likelihood of hyperglycemia during times of increased insulin requirements for the user. The activity mode of operation may be manually activated by the user or may be activated automatically by the controller. The controller may automatically activate the activity mode of operation based on a detected activity level of the user and / or a detected location of the user.

The invention relates to a lactic acid bacterium capable of reducing fat, resisting inflammation and reducing blood sugar, which is classified and named as pediococcus acidilactici XJ335, and is preserved in the China General Microbiological Culture Collection Center (CGMCC), the preservation number is CGMCC No.30093, the preservation date is March 22, 2024, and the preservation address is No.3, Yard 1, Beichen West Road, Chaoyang District, Beijing. The strain can achieve the fat reducing effect by adjusting the abundance of intestinal flora; the levels of IL-6 and TNF-alpha in serum of diabetic mice are remarkably improved through regulation, so that the anti-inflammatory effect is achieved; various cardiovascular diseases of atherosclerosis are prevented by adjusting the levels of TC, TG, HDL-C and LDL-C; by reducing FINS and HOMA-IR levels and improving HOMA-IS, HOMA-beta and QUICKI value levels, insulin resistance of a body is reduced, insulin sensitivity and pancreas islet beta cell functions of the body are improved, gene expression related to blood sugar regulation is regulated, and an excellent blood sugar reducing effect is achieved in the body.

The invention relates to the technical field of biological medicines, in particular to application of N-acetyl serotonin in prevention and treatment of diabetes mellitus, and tests show that NAS has an obvious improvement effect on symptoms of weight loss, water intake increase and diet increase of T2DM mice; the NAS is used for improving the fasting blood glucose and the glucose tolerance level of the T2DM mouse; the NAS reduces the glycated serum protein and insulin resistance level of the T2DM mouse; the pancreatic beta cell function and insulin sensitivity of the T2DM mouse are improved. Therefore, the medicine N-acetyl serotonin has a good clinical application prospect in treating the type 2 diabetes mellitus and has important significance in developing a novel medicine composition for treating the type 2 diabetes mellitus.

Disclosed here is the method of treating general inflammation, metabolic health / insulin resistance / glycemic-glucose uptake & management (affecting skeletal muscle, liver, adipose, skin, gut, fibro-connective / joint, kidney, brain / CNS and other tissues), systemic inflammation, Immuno-modulation & Metabolic Syndrome / Nonalcoholic fatty liver disease (NAFLD), and provide Immuno-modulation, Insulin Sensitizing and Immuno-Metabolic benefits with at least one short fatty acid, such as butyrate or butyric acid in form of tributyrin, used in conjunction with one cannabinoid, such as cannabidiol or CBD, and with at least one terpene, such as beta-caryophyllene or BCP.

This invention relates to the field of traditional Chinese medicine (TCM) technology, and more particularly to the application of TCM compositions in the preparation of drugs for the prevention and treatment of diabetes. The TCM composition of this invention includes *Sedum sarmentosum*, seaweed, oyster shell, hawthorn, *Siegesbeckia orientalis*, *Schisandra chinensis*, and *Polygonum cuspidatum*. This invention has found that this composition can significantly reduce blood glucose levels in type 2 diabetic rats and increase serum insulin levels and insulin sensitivity index in rats. Moreover, the compound combination drug for treating diabetes is an existing TCM preparation, safe to use, and its preparation method is simple, rapid, efficient, and easy to operate. The prepared mixtures, tablets, capsules, and micro-pills are easy to carry and convenient to take.

The invention relates to the technical field of insulin resistance reversal, in particular to a composition with an insulin resistance reversal component and a preparation method thereof.The composition comprises quercetin, procyanidine, malic acid, magnesium carbonate, zinc lactate and cereals, fasting blood glucose, fasting insulin and an insulin resistance index can be reduced through synergistic interaction of all the components, and the insulin resistance index can be reduced; according to the traditional Chinese medicine composition, the insulin sensitivity index is improved, and the problems that in the prior art, traditional Chinese medicine compositions are complex in component, effective components capable of reversing insulin resistance and the synergistic mechanism are unclear, and the content of the effective components in the same medicine is inconsistent due to the influence of the growth environment, so that the treatment effect is unpredictable are solved.

The invention provides a preparation method of probiotic fermented polygonatum sibiricum polysaccharide, and belongs to the field of traditional Chinese medicinal material processing. The preparation method comprises the following steps: (1) adding cellulase and pectinase into polygonatum kingianum, carrying out water extraction, carrying out enzyme deactivation after water extraction, and carrying out suction filtration to obtain filtrate; (2) preparing bacillus DU-106 and lactobacillus plantarum nbk-MA2 into bacterial powder, and adding water to obtain bacterial liquid; mixing the bacterial liquid with the filtrate, fermenting, performing suction filtration, and centrifuging to obtain supernate; performing alcohol precipitation to remove protein; carrying out ethanol precipitation by using absolute ethyl alcohol again, collecting the precipitate after centrifuging, and carrying out redissolution, dialysis and freeze-drying to obtain fermentation modified crude polysaccharide; and (3) purifying the fermented and modified crude polysaccharide to obtain a purified polysaccharide component. The obtained probiotic fermented polygonatum sibiricum polysaccharide has the effect of losing weight, and can obviously improve the obesity characteristics of mice, specifically, reducing body weight, reducing fat, reducing serum liver lipid level, relieving serum liver inflammation of the mice, weakening blood glucose insulin sensitivity, repairing liver injury and the like.

The invention discloses an endogenous small molecule metabolite for treating obesity and related metabolic diseases thereof, and belongs to the field of biological medicine. Specifically, the invention relates to application of hippuric acid in preparation of anti-obesity drugs. The invention discloses a technical scheme for treating obesity and related metabolic disorders by hippuric acid, and overcomes the defects of single curative effect, larger side effect or unclear action mechanism and the like in the prior art through the advantages of targeted improvement of liver fatty degeneration, improvement of insulin sensitivity, higher potential safety, provision of a new treatment strategy and the like. The method has remarkable technical progress and clinical application value.

The invention relates to the technical field of biology, in particular to a method for relieving high-starch-induced liver injury and glucose metabolism disorder of perches. The feed formula provided by the invention comprises the following components in percentage by weight: 20-22% of cassava starch, 2-6% of mulberry leaf polysaccharide and the like. The mulberry leaf polysaccharide and high-content starch in the feed form efficient synergy, so that the growth performance of the weever is remarkably improved, accumulation of liver glycogen and fat is effectively reduced, and the health condition of the liver is remarkably improved; meanwhile, the blood sugar regulation capability of the weever is also optimized, the insulin resistance caused by high starch diet is reduced, and the insulin sensitivity is enhanced; and by activating a PI3K / Akt signal path and other mechanisms, a glucose metabolism path is optimized, and efficient utilization of energy is promoted. The feed disclosed by the invention is economical and efficient in formula, provides solid scientific support for healthy culture of perches, and powerfully promotes sustainable development of aquaculture industry.

The invention provides a formula for regulating hyperglycemia by probiotics and a preparation method of the formula, and relates to the technical field of the probiotics, the formula comprises two formulas, the formula I comprises the probiotics, hypoglycemic pepper, raw malt, burdock, snow pear and the like, and the formula II comprises the probiotics, the hypoglycemic pepper, the raw malt, the burdock, the snow pear and the like; and the formula II consists of inonotuso bliquus polysaccharide, schizophyllum commune, chromium yeast, soybean peptide powder and lactobacillus fermentation product powder. The two formulas can be taken independently, alternately or jointly, and are used for regulating the blood sugar level of patients with hyperglycemia or type 2 diabetes mellitus. The probiotic powder contains a plurality of strains with high activity and high viable count, and plays a role in digesting and absorbing basic metabolism. The natural components in the formula have a hypoglycemic effect, and play a role in improving the secretion function of pancreas islet beta cells, improving insulin sensitivity, delaying absorption of carbohydrates, helping produce saliva and slake thirst, diluting blood sugar and other mechanisms.

The present invention relates to a peptide complex having an antidiabetic activity and to a use thereof. The peptide complex of the present invention promotes uptake of glucose into cells, suppresses insulin resistance signals, promotes insulin sensitivity signals, and suppresses the death of pancreatic beta cells, which are insulin-producing cells, thereby exhibiting an effect of lowering blood glucose levels. In addition, the present invention relates to a peptide having an antidiabetic activity and an antiobesity activity and to a use thereof. The peptide of the present invention has an activity of suppressing insulin resistance signals, promoting insulin sensitive signals, and promoting fat decomposition in adipocytes.

The invention discloses a microneedle raw material composition, a microneedle formed by the microneedle raw material composition and an ultrasonic regulation and control gene editing system, the microneedle raw material composition comprises CRISPRa-UCP1 plasmid (aUCP1) loaded in a zinc-based porphyrin metal organic framework MOF (Zn-TCPP) and used for up-regulating UCP1, and the MOF is MOF modified by mPEG-PEI. And the browning of white fat cells is promoted through the controllable release of the CRISPRa-UCP1 system. Obese mice treated with this ultrasound gene therapy show significant improvements in glucose tolerance and insulin sensitivity, successfully achieving weight loss and inhibiting weight rebound. The research provides a new standard treatment mode for gene therapy of obesity and other metabolic diseases.

Disclosed herein is related to a method for extending lifespan and / or delaying aging in a subject; the method comprises administering to the subject with an effective amount of (24S)-3β-hydroxy-5α-stigmastan-6-one, wherein the delaying aging comprises increasing vitality, muscle strength or motor coordination, insulin sensitivity, or basal metabolic rate; and / or reducing muscle weakness, loss of balance, hair graying, kyphosis, or hyperglycemia. Also encompassed in the present disclosure are methods for promoting weight loss or treating type 2 diabetes mellitus in a subject, in which the methods comprise administering to the subject an effective amount of (24S)-3β-hydroxy-5α-stigmastan-6-one.

The invention relates to a mitochondrial uncoupling inhibitor sustained-release nanodot, a preparation method thereof and application of the nanodot in type 2 diabetes mellitus, and belongs to the technical field of nano-drugs. According to the preparation method disclosed by the invention, glycine and genipin are subjected to Schiff reaction to prepare the slow-release nanodot, and the slow-release nanodot is of a monodisperse spherical structure, has surface negative charges, and can slowly release genipin under physiological conditions, so that the mitochondrial protection effect of the genipin is fully exerted. The mitochondrial uncoupling inhibitor slow-release nanodot prepared by the invention can obviously improve the mitochondrial membrane potential, increase the cell ATP content, effectively inhibit mtDNA release under the stimulation of IL-1beta and palmitic acid, effectively inhibit STING inflammation pathway activation under the stimulation of IL-1beta and PA, obviously reduce pancreatic beta cell apoptosis, obviously relieve endoplasmic reticulum stress, and can be used for preparing the mitochondrial uncoupling inhibitor slow-release nanodot. The T2DM mouse blood sugar is obviously reduced, the glucose tolerance dose and the insulin sensitivity are improved, and good biocompatibility is achieved.

The invention discloses mesoporous polydopamine nanoparticles loaded with texipatide as well as a preparation method and application of the mesoporous polydopamine nanoparticles. The preparation method of the mesoporous polydopamine nanoparticles loaded with the texipatide comprises the following steps: firstly, mixing dopamine hydrochloride and a nonionic copolymer under the condition of a solvent, then sequentially adding a hydrophobic pore-enlarging agent and a catalyst, and reacting to obtain the mesoporous polydopamine nanoparticles, the preparation method comprises the following steps: preparing mesoporous polydopamine nanoparticles, dispersing the mesoporous polydopamine nanoparticles in a water solvent, adding texipatide, and carrying out a mixing reaction to obtain the texipatide-loaded mesoporous polydopamine nanoparticles. The mesoporous polydopamine nanoparticles loaded with texipatide prepared by the preparation method not only have excellent drug encapsulation efficiency and drug slow release effect, but also can effectively reduce the body weight and random blood glucose of a patient and remarkably improve the glucose tolerance and insulin sensitivity of the patient when being used for treating obesity, so that the mesoporous polydopamine nanoparticles loaded with texipatide can be used for treating obesity. And an energy consumption rate.

The invention discloses a composite combined preparation for synergistically treating and conditioning diabetes, relates to the technical field of foods, health foods or dietary supplements for adjuvant therapy and health care of diabetes, and in particular relates to a composite combined preparation for synergistically treating and conditioning diabetes. The preparation comprises albumin peptide, saussurea involucrata culture, vitamin B1, vitamin B2, wheat oligopeptide, corn oligopeptide, collagen peptide, mulberry leaf extract, rhizoma polygonati extract, sea-buckthorn extract, isomaltitol, maltodextrin, ginseng extract and bitter gourd extract. Through the synergistic effect of all the components, comprehensive auxiliary conditioning on diabetes is realized from multiple targets of maintaining colloid osmotic pressure and nutrition, regulating glycolipid metabolism in multiple ways, protecting pancreatic beta cell functions, enhancing insulin sensitivity, preventing nerve and blood vessel complications, meeting special diet requirements and the like. The composition can be prepared into food, health-care food or dietary supplement and other dosage forms.

This invention is in the area of improved anti-aP2 antibodies and antigen binding agents, and compositions thereof, which target the lipid chaperone aP2 / FABP4 (referred to as “aP2”) for use in treating disorders such as diabetes, obesity, cardiovascular disease, fatty liver disease, and / or cancer, among others. In one aspect, improved treatments for aP2 mediated disorders are disclosed in which serum aP2 is targeted and the biological activity of aP2 is neutralized or modulated using low-binding affinity aP2 monoclonal antibodies, providing lower fasting blood glucose levels, improved systemic glucose metabolism, increased systemic insulin sensitivity, reduced fat mass, reduced liver steatosis, reduced cardiovascular disease and / or a reduced risk of developing cardiovascular disease.

The invention discloses a microneedle raw material composition as well as a microneedle and a sonodynamic system formed by the microneedle raw material composition. The microneedle raw material composition comprises a zinc-based porphyrin metal organic framework MOF (Zn-TCPP) modified by mPEG-PEI. The sonodynamic system provided by the invention can kill redundant white fat cells. Obese mice treated with this ultrasound gene therapy show significant improvements in glucose tolerance and insulin sensitivity, successfully achieving weight loss and inhibiting weight rebound.

The invention discloses a pharmaceutical application of a 3-phenylglutaric acid derivative and a pharmaceutical composition. The 3-phenylglutaric acid derivative can be used for preparing an FASN inhibition drug. The 3-phenylglutaric acid derivative micromolecule 84-B10 can inhibit FASN in a targeted manner, is used for inhibiting the activity of the FASN, promoting the degradation of the FASN and relieving weight gain, liver fat accumulation, insulin sensitivity decline and glucose tolerance impairment caused by high calorie intake, and can be used for preparing medicines for preventing and treating metabolism-related fatty liver diseases.

The present invention provides nanoparticles or compositions thereof comprising resveratrol and / or quercetin, or derivatives, prodrugs, or pharmaceutically acceptable salts thereof, at least one lipid, at least one surfactant, and at least one vitamin E. In some embodiments, the nanoparticles or compositions thereof further comprise at least one targeting agent. In some embodiments, the nanoparticles or compositions thereof are targeted for an adipose tissue of interest. In some aspects, the present invention provides methods of activating brown adipose tissue or browning white adipose tissue or beige adipose tissue of interest. In some aspects, the present invention provides methods of reducing body fat, inducing weight loss, and / or improving glucose homeostasis and insulin sensitivity. In some aspects, the present invention provides methods of optimizing the composition of the gut microbiota. In some aspects, the present invention provides methods of treating or preventing various diseases or disorders, such as obesity.

The invention provides a tillite health-care wine production process, and relates to the technical field of health-care wine brewage, the tillite health-care wine production process comprises the following steps: S1, raw material preparation, S2, raw material treatment: crushing the dried raw materials through crushing operation; s3, stirring: putting the powdery raw materials formed in the step S2 into a reaction kettle; s4, purifying and filtering; s5, cooking: cooking the tillite extracting solution and common food materials for wine brewing; s6, performing fermentation: performing fermentation on the food material extracting solution obtained in the step S5, honey and yeast together; s7, sterilization and disinfection; s8, blending: blending the sterilized raw stock of the brewed wine in the S7 with distilled wine; s9; performing packaging; the traditional Chinese medicine composition is helpful for regulating the metabolic process in the body and regulating blood fat, insulin sensitivity and vasodilation, so that blood sugar, blood pressure and blood fat are reduced; and by taking a proper amount of the health-care tea, the immunity can be enhanced, the beauty is maintained, the senescence is delayed and the sexual function is improved.

The application discloses a benzothiophenone derivative, a preparation method and application thereof. The benzothiophenone derivative, a tautomer, an optical isomer, a hydrate, a solvate, a pharmaceutically acceptable salt or a prodrug thereof, and the chemical structure of the benzothiophenone derivative is shown as formula (I), wherein R is any one of the following groups: a substituted alkane and N-benzyl-2-chloroformamide. The benzothiophenone derivative can regulate a PPARγ target as an anti-type 2 diabetes drug, can reserve insulin sensitivity, can avoid related side effects caused by a PPARγ full agonist, and has a 'highly efficient and safe' hypoglycemic effect.

This invention relates to the application of oridonin in the preparation of agents that improve muscle function, specifically by improving skeletal muscle dysfunction, enhancing insulin sensitivity, promoting myoblast differentiation into myotube cells, and / or increasing myoblast insulin sensitivity. Using an in vitro C2C12 myoblast model, this invention demonstrates that oridonin can promote myoblast differentiation and growth and increase C2C12 myoblast insulin sensitivity. Through an obesity-induced skeletal muscle dysfunction model, it is demonstrated that oridonin can improve skeletal muscle dysfunction and insulin resistance by increasing muscle strength, muscle endurance, muscle mass, and reducing muscle lipid accumulation. This invention provides new insights for drug research on improving skeletal muscle dysfunction and enhancing insulin sensitivity, and also enriches the pharmacological system of oridonin.

The invention relates to application of an asparagine endopeptidase inhibitor in preparation of a medicine for improving insulin resistance. According to the application, starting from inhibiting the aging driving factor AEP, the AEP inhibitor is tried to be applied to the research of insulin resistance for the first time, and the AEP inhibitor is found to be capable of remarkably improving glucose tolerance and insulin sensitivity. Therefore, the invention provides the application of the asparagine endopeptidase inhibitor in preparation of the medicine for improving insulin resistance. Experiments prove that the AEP inhibitor not only can significantly enhance insulin sensitivity of old mice and improve glucose tolerance, but also can reduce serum low-density lipoprotein cholesterol and lactic dehydrogenase levels, shows multiple improvement effects on glucose metabolism and lipid metabolism, and also can be used for preparing the AEP inhibitor. After long-term administration, obvious toxic and side effects are not found in pathological examinations of blood routine examination, urine routine examination, heart, liver, spleen, lung, kidney and other important organs, so that the traditional Chinese medicine composition is proved to have good safety and is suitable for long-term intervention of chronic diseases.

The present application relates to the technical field of reversing insulin resistance, and particularly relates to a composition with components for reversing insulin resistance and a preparation method thereof, the composition comprising quercetin, procyanidin, malic acid, magnesium carbonate, zinc lactate and grains, and through synergistic effects of the components, the composition can reduce fasting blood glucose, fasting insulin and insulin resistance index, and improve insulin sensitivity index, and overcomes the problems in the prior art that the components of the traditional Chinese medicine composition are complex, the effective components for reversing insulin resistance and the synergistic mechanism are not clear, and the content of the effective components in the same medicine is not consistent due to the influence of the growth environment, resulting in unpredictable treatment effect.

The invention relates to mulberry oligosaccharide, a preparation method thereof and application of the mulberry oligosaccharide in blood sugar regulation and control. The mulberry oligosaccharide is obtained by processing mulberries through a large number of researches and specific process steps of enzymolysis, selenic acid modification, plasma treatment and the like, so that the stability of the mulberry oligosaccharide can be obviously improved, the inhibition capability on alpha-glucosidase is obviously improved, the sugar tolerance condition of diabetic mice is improved, the blood sugar level is stabilized, and the application prospect is wide. Meanwhile, the insulin sensitivity of the body can be improved, the insulin resistance degree can be improved, the absorption and utilization of insulin to glucose can be improved, the SOD activity of the body can be improved, and the MDA content can be reduced, so that the development of diabetes can be effectively slowed down. In addition, natural mulberry is used as a main preparation raw material, no harmful chemical component is added, the cost is low, the safety is good, and great social significance is achieved.